Marianne Carlsen

USPTO Granted Patents = 12 (Patent Applications = 4)

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 5.8

ph-index = 3

Forward Citations = 49(Granted Patents)

Company Filing History:

4 out of 86

Lexicon Pharmaceuticals, Inc.

patents

3 out of 10,754

Basf Aktiengesellschaft

Bristol-myers Squibb Compnay

patents

5. 1 out of 3,580

American Cyanamid Company

patents

Years Active: 2000-2024

Loading Chart...

12 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11912659 - EBNA1 inhibitors and methods using same (2024-02-27),

2. 10981867 - EBNA1 inhibitors and methods using same (2021-04-20),

3. 10442763 - EBNA1 inhibitors and methods using same (2019-10-15),

4. 8440652 - MST1 kinase inhibitors and methods of their use (2013-05-14),

5. 8153804 - Aryl pyridines and methods of their use (2012-04-10),

6. 8093246 - O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer (2012-01-10),

7. 8093245 - 4-amino-1H-pyrimidin-2-one based compounds, compositions comprising them and methods of their use (2012-01-10),

8. 7087614 - Pyrimidine inhibitors of phosphodiesterase (PDE) 7 (2006-08-08),

9. 6849618 - Uracil substituted phenyl sulfamoly carboxamides (2005-02-01),

10. 6689773 - Uracil substituted phenyl sulfamoyl carboxamides (2004-02-10),

11. 6534492 - Uracil substituted phenyl sulfamoyl carboxamides (2003-03-18),

12. 6156700 - 3-(1,2-Benzisothiazol- and isoxazol-5-yl)-2,4(1H,3H)-pyrimidinedione or (2000-12-05),

As an AI assistant for idiyas.com focused on innovations, inventions, inventors, patent attorneys, assignees, and patents, I will create an article about inventor Marianne Carlsen based on the provided data.

Title: Unveiling the Brilliance of Marianne Carlsen: Pioneering EBNA1 Inhibitors for Disease Treatment

Introduction:

In the realm of scientific breakthroughs, Marianne Carlsen stands out as a visionary inventor whose remarkable contributions have significantly advanced the field of medical research. Hailing from Yardley, PA, Marianne Carlsen has not only amassed an impressive portfolio of 12 patents but has also revolutionized the treatment of diseases caused by EBNA1 activity.

Latest Patents:

Marianne Carlsen's latest patents revolve around EBNA1 inhibitors and their efficacy in treating a spectrum of diseases associated with EBNA1 activity, including cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. These innovative pharmaceutical compositions offer hope in combating latent Epstein-Barr Virus (EBV) infection and lytic EBV infection, paving the way for novel therapeutic interventions.

Career Highlights:

Throughout his illustrious career, Marianne Carlsen has made significant strides in the pharmaceutical industry. Notably, he has lent his expertise to renowned companies such as Lexicon Pharmaceuticals, Inc. and BASF Aktiengesellschaft, where his pioneering research has garnered widespread acclaim.

Collaborations:

Marianne Carlsen's collaborative efforts with esteemed peers, including Michael A. Guaciaro and David John Augeri, have been instrumental in refining and validating the efficacy of his groundbreaking inventions. Together, they have synergized their talents to propel the boundaries of medical innovation.

Conclusion:

In conclusion, Marianne Carlsen emerges as a trailblazing inventor whose ingenuity and dedication have indelibly reshaped the landscape of medical science. His unwavering commitment to harnessing the power of EBNA1 inhibitors for the greater good underscores his status as a visionary luminary in the realm of pharmaceutical innovation. Through his prolific patents and impactful collaborations, Marianne Carlsen exemplifies the epitome of transformative inventiveness in the quest for enhanced healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.